Empowering people with mobility impairments to manage pain, spasticity and sleep naturally – with confidence
For many people with mobility impairments, daily life is shaped by spasms, persistent pain, and nights of broken sleep. Around the world, patients and clinicians are turning to cannabis-based medicines as a gentle, scientifically supported option that can help restore comfort and control.
Until now, almost all high-quality medical cannabis produced in South Africa has been exported to meet demand in Europe, North America and Australia. South Africans had limited access to the very products grown and manufactured locally. That is finally changing.
One of the first locally developed, locally available options is B25 NOIA, a NAPPI-coded, South African–manufactured oral cannabis medicine from AKOS BIO.
Growing Evidence, Growing Hope
Research into cannabis medicines continues to expand, and the findings are consistent:
- Reduced spasticity and muscle spasms;
- Lower pain levels;
- Improved sleep quality; and
- Better mood and daily functioning.
Studies in Multiple Sclerosis and spinal cord injury show significant improvements in stiffness, spasm severity and sleep, with no evidence of long-term cognitive or psychological harm under regulated medical use. For many, cannabis-based medicines have become a dependable part of symptom management.
Introducing B25 NOIA: Compassionate Science, Locally Made
B25 NOIA uses the same active components found in internationally studied cannabis medicines but is produced locally under strict quality standards. Because it is NAPPI-coded, it fits into established medical-aid and Department of Health pathways – bringing long-awaited access to South African patients.
As Connor Davis, founder of AKOS BIO, explains: “For years, South Africa has exported world-class medical cannabis overseas. We are proud to finally introduce the first South African-manufactured cannabis medicines made for South Africans who stand to benefit from safe, reliable access.”
A Patient-First Approach: “Start Low, Go Slow”
Trying a new medicine can feel daunting, especially a cannabis-based one. AKOS BIO’s clinical team focuses on reassurance, personalised dosing and careful medical oversight.
Their principle: “Start low, go slow.” Patients begin with a gentle dose – around 0.1 milligram, similar in effect to a mild OTC analgesic – and the dosage is gradually adjusted with a doctor until optimal relief is achieved.
More Control, More Confidence
Patients often report a sense of autonomy as they learn to understand their pain, spasms and sleep patterns with clinical guidance. Unlike many traditional medications, occasional slight overuse of B25 NOIA typically results only in mild, short-lived effects such as drowsiness or increased appetite – not dangerous complications.
Why It Matters
Many people in the mobility-impairment community live with unrelenting pain and spasticity. Evidence-based cannabis treatments – when prescribed responsibly – offer a safe, regulated and compassionate option.
Now, with locally manufactured, NAPPI-coded access, South Africans can finally benefit from the high-quality products that were once exported abroad.
For information and guidance accessing AKOS BIO’s medical cannabis products WhatsApp 071 2555 701 or visit the AKOS BIO website here.
